文献速递肝病

alfapump系统对肝硬化伴复发性或难治性腹水患者的腹水控制及生活质量的影响

The Effects of Alfapump on Ascites Control and Quality of Life in Patients With Cirrhosis and Recurrent or Refractory Ascites.
PubMed 文献 · Am J Gastroenterol · 2025-01-06

本研究纳入40例肝硬化合并难治性腹水且30天内需≥2次治疗性腹腔穿刺的患者,植入alfapump后随访24个月;6个月时腹腔穿刺需求从每月3.2±1.5次降至0.2±0.6次(P<0.001),77%患者降幅≥50%,腹水相关症状评分改善,但15%泵因器械相关不良事件取出。

要点

  • 6个月时腹腔穿刺需求由每月3.2±1.5次降至0.2±0.6次(P<0.001),77%患者降幅≥50%。
  • 6个月内6例(15%)泵因器械相关不良事件取出,其中泵部位皮肤侵蚀3例(7.5%)、膀胱不适3例(7.5%)。
  • 腹水相关症状评分由51.0±19.3降至32.2±21.9(P<0.001),生活质量简表36生理维度改善(P<0.001),心理维度未改善。

核心结论

  • alfapump系统有效控制腹水并改善生活质量,在特定难治性腹水患者中可考虑作为反复治疗性腹腔穿刺的替代方案。
  • 并发症发生率与难治性腹水患者预期水平相似。

研究设计与样本

  • 纳入40例肝硬化合并难治性腹水、植入前30天内需≥2次治疗性腹腔穿刺的患者,植入后随访24个月。
  • 主要疗效终点为6个月时腹腔穿刺需求的减少;安全性终点为导致干预、取出或死亡的器械相关不良事件。

主要发现

  • 腹腔穿刺需求由植入前每月3.2±1.5次降至植入后6个月每月0.2±0.6次(P<0.001),77%患者降幅≥50%。
  • 6个月内6台泵(15%)因器械相关不良事件取出,其中泵部位皮肤侵蚀3例(7.5%)、膀胱不适3例(7.5%)。
  • 植入后0-6个月发生24例肾脏事件,其中16例为可迅速逆转的1期急性肾损伤。
  • 腹水相关症状评分(Ascites Q)由植入前51.0±19.3改善至植入后6个月32.2±21.9(P<0.001)。
  • 生活质量简表36生理维度改善(P<0.001),心理维度未改善;植入后6个月内5例死亡与器械或alfapump治疗无直接关系。

临床怎么用

  • 作者认为,alfapump系统可考虑作为特定难治性腹水患者反复治疗性腹腔穿刺的替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The alfapump system has been shown to be a possible alternative to repeat therapeutic paracentesis (TP) in selected patients with refractory ascites (RA). The objective of this study was to assess the safety and efficacy of alfapump on ascites control and quality of life in these patients. METHODS: Patients with cirrhosis and RA requiring ≥2 TPs 30 days prior were enrolled and followed for 24 months postimplant. Primary efficacy end point assessed at 6 months was reduction in paracentesis requirement; safety end point was device-related adverse events resulting in intervention, explant, or death. RESULTS: Forty patients with RA (mean Model of End-stage Liver Disease-Sodium: 15 ± 4) received an alfapump. TP requirement was decreased from 3.2 ± 1.5 sessions per month preimplant to 0.2 ± 0.6 sessions per month at 6 months postimplant ( P < 0.001), with 77% of patients having ≥50% reduction. Six pumps (15%) were explanted within 6 months due to device-related adverse events, 3 (7.5%) due to pump site skin erosion, and 3 (7.5%) due to bladder discomfort. Twenty-four renal events occurred in the 0-6 month postimplant period; 16 cases were readily reversible stage 1 acute kidney injury. Ascites-related symptoms assessed with an Ascites Q score improved from 51.0 ± 19.3 preimplant to 32.2 ± 21.9 at 6 months postimplant ( P < 0.001). Physical but not mental components of Short Form 36 improved ( P < 0.001). The 5 deaths within 6 months postimplant were not directly related to the device or alfapump therapy. DISCUSSION: The alfapump system effectively controlled ascites, which improved quality of life. It may be considered as an alternative to repeat TP in select patients with RA. Complication rates were similar to those expected in patients with RA.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Wong F, Vagas HE, Reddy KR, et al. The Effects of Alfapump on Ascites Control and Quality of Life in Patients With Cirrhosis and Recurrent or Refractory Ascites. Am J Gastroenterol. 2025. PMID: 39760647. doi:10.14309/ajg.0000000000003300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。